Diminished ovarian reserve in adolescent cancer survivors treated with heavy metal chemotherapy.
Diminished ovarian reserve in adolescent cancer survivors treated with heavy metal chemotherapy.
复制标题
接受重金属化疗的青少年癌症幸存者的卵巢储备功能下降。
DOI：
10.1002/pbc.30448
复制
发表时间：
2023
影响因子：
3.2
通讯作者：
Cherven,Brooke
中科院分区：
文献类型：
--
作者：
Pruett,Megan;WilliamsonLewis,Rebecca;Klosky,JamesL;Effinger,KarenE;Meacham,LillianR;Cherven,Brooke
重金属化疗在多大程度上会导致与治疗相关的卵巢损伤仍存在争议。从39名11岁及以上的儿童癌症幸存者的医疗记录中提取了癌症治疗完成一年多后测量的抗苗勒氏激素(AMH)水平，她们唯一的性腺毒性暴露是重金属化疗。在接受顺铂治疗的幸存者中，有五分之一的人在最后一次测量中发现AMH水平表明卵巢储备减少。在被诊断为青春期周围年龄(即10-12岁)的患者中，观察到低AMH的聚集性。这些发现可能支持重金属化疗后性腺损伤的风险很小，但存在。
The extent to which heavy metal chemotherapy results in treatment‐related ovarian damage is controversial. Anti‐Mullerian hormone (AMH) levels measured more than 1 year after cancer therapy completion were abstracted from the medical records of 39 female survivors of childhood cancer aged 11 years and older, whose only gonadotoxic exposure was heavy metal chemotherapy. One‐fifth of survivors who received cisplatin had AMH levels indicative of diminished ovarian reserve at last measurement. There was an observed clustering of low AMH in patients diagnosed in the peripubertal age range (i.e., 10–12 years). These findings may support a small, but present, risk of gonadal damage after heavy metal chemotherapy.